Additional Hetero Ring Containing Patents (Class 546/125)
-
Publication number: 20030236270Abstract: The invention provides compounds of Formula I: 1Type: ApplicationFiled: February 14, 2003Publication date: December 25, 2003Inventors: Eric Jon Jacobsen, Jason K. Myers, Daniel Patrick Walker, Donn G. Wishka, Steven Charles Reitz, David W. Piotrowski, Brad A. Acker, Vincent E. Groppi
-
Publication number: 20030236405Abstract: Compounds of the formula 1Type: ApplicationFiled: February 27, 2003Publication date: December 25, 2003Inventors: Daniel Yohannes, Mark W. Bundesmann
-
Patent number: 6667314Abstract: The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.Type: GrantFiled: May 25, 2001Date of Patent: December 23, 2003Assignee: Pfizer, Inc.Inventors: Manoussos Perros, David Anthony Price, Blanda Luzia Christa Stammen, Anthony Wood
-
Publication number: 20030225268Abstract: Compounds of formula I: 1Type: ApplicationFiled: April 11, 2003Publication date: December 4, 2003Inventors: William H. Bunnelle, Daniela Barlocco Cristina, Jerome F. Daanen, Michael J. Dart, Michael D. Meyer, Keith B. Ryther, Michael R. Schrimpf, Kevin B. Sippy, Richard B. Toupence
-
Patent number: 6656951Abstract: Compounds of the formula: are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia and also treatment of disorders related to excessive serotonergic stimulation, such as anxiety, aggression and stress, and for the control of various physiological phenomena, such as appetite, thermoregulation, sleep and sexual behavior, which are known to be, at least in part, under serotonergic influence.Type: GrantFiled: April 23, 2002Date of Patent: December 2, 2003Assignee: WyethInventors: Adam M. Gilbert, Gary P. Stack
-
Publication number: 20030220366Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.Type: ApplicationFiled: February 6, 2003Publication date: November 27, 2003Inventors: Simon Bailey, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen
-
Patent number: 6645977Abstract: The present invention discloses compounds of formula (1) any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein - - - - is a single or a double bond; R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; and R1 is (a), wherein R2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, amino; or aryl which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalklyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, thioalkoxy, thiocycloalkoxy, methylenedioxy, aryloxy, halogen, CF3, OCF3, CN, amino, aminoacyl, nitro, aryl and a monocyclic 5 to 6-membered heteroaryl group; a monocyclic 5 to 6-membered heteroaryl group which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, thioalkoxy, thiocycloalkoxy, methylenedioxy, aryloxy, halogen,Type: GrantFiled: November 29, 1999Date of Patent: November 11, 2003Assignee: NeuroSearch A/SInventors: Dan Peters, Gunnar M. Olsen, Simon Feldbaek Nielsen, Elsebet Ostergaard Nielsen
-
Publication number: 20030207913Abstract: The invention provides compounds of Formula I:Type: ApplicationFiled: November 6, 2002Publication date: November 6, 2003Inventors: David W. Piotrowski, Jason K. Myers, Bruce N. Rogers, Eric Jon Jacobsen, Alice L. Bodnar, Vincent E. Groppi, Daniel Patrick Walker, Brad A. Acker
-
Publication number: 20030207860Abstract: The present invention discloses compounds which, are novel receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.Type: ApplicationFiled: July 24, 2002Publication date: November 6, 2003Applicant: Schering CorporationInventors: Andrew W. Stamford, Ying Huang, Guoqing Li
-
Patent number: 6642246Abstract: Compounds of formula I wherein A represents: and R, R1, R2, R3 and R4 are as defined in the specification, pharmaceutically-cceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.Type: GrantFiled: April 15, 2002Date of Patent: November 4, 2003Assignee: Astrazeneca ABInventor: Richard Schmiesing
-
Publication number: 20030199545Abstract: The present invention relates to new compounds of general formula 1 1Type: ApplicationFiled: March 25, 2003Publication date: October 23, 2003Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Matthias Grauert, Michael P. Pieper, Gerald Pohl, Georg Speck, Steffen Breitfelder
-
Patent number: 6617339Abstract: Compounds of formula (I) as defined herein, or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, are useful as antibacterial agents. Processes for their manufacture and pharmaceutical compositions containing them are described.Type: GrantFiled: December 5, 2000Date of Patent: September 9, 2003Assignee: Syngenta LimitedInventor: Michael Barry Gravestock
-
Patent number: 6586430Abstract: Compounds of Formula 1 [Region &agr;]-[Region &bgr;]-[Region &ggr;]-[Region &dgr;] (I) which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and methods of treatment using these compounds.Type: GrantFiled: December 1, 1999Date of Patent: July 1, 2003Assignee: Pfizer Inc.Inventors: Duncan Robert Armour, David Anthony Price, Blanda Luzia Christa Stammen, Anthony Wood, Manoussos Perros, Martin Paul Edwards
-
Patent number: 6586446Abstract: The present application describes modulators of CCR3 of formula (I): A—E—NR1—G (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.Type: GrantFiled: October 13, 2000Date of Patent: July 1, 2003Assignee: Bristol-Myers Squibb CompanyInventors: John V Duncia, Joseph B Santella, III, Daniel S Gardner, Dean A Wacker
-
Publication number: 20030119847Abstract: Novel compounds of the formula 1Type: ApplicationFiled: November 6, 2002Publication date: June 26, 2003Applicant: Schering CorporationInventors: Deen Tulshian, Ginny D. Ho, Fay W. Ng
-
Publication number: 20030105124Abstract: This invention relates to compounds of the general formula (1): 1Type: ApplicationFiled: April 27, 2000Publication date: June 5, 2003Inventor: Susan Beth Sobolov-Jaynes
-
Patent number: 6537522Abstract: Iodinated neuroprobes for mapping monoamine reuptake sites in the brain, and particularly iodinated neuroprobes that can also serve as radiotracers for use in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging of such reuptake sites, are disclosed. Precursors of radiolabeled iodinated neuroprobes, both with and without a radiotracer atom, and kits for preparing the radiolabeled iodinated neuroprobes are also disclosed.Type: GrantFiled: May 12, 1998Date of Patent: March 25, 2003Assignee: Amersham PLCInventors: John L. Neumeyer, Richard A. Milius, Robert B. Innis, Gilles Tamagnan, Shaoyin Wang
-
Patent number: 6531484Abstract: Pyrrolidine compounds of Formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, j, k, 1, m, and n are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: October 10, 2001Date of Patent: March 11, 2003Assignee: Merck & co., Inc.Inventors: Christopher A. Willoughby, Keith Rosauer, Kevin T. Chapman, Sander G. Mills, Dong-Ming Shen, Min Shu
-
Publication number: 20030028013Abstract: Conformationally restricted 2′, 4′-bridged nucleoside analogues are described herein. The compounds can be prepared by cyclization at C2′ and C4′ of nucleosides through a linker or linking molecule. These novel nucleosides have a desired, locked sugar pucker and are potentially useful as pharmaceutical ingredients, and especially for use in treatment of HCV.Type: ApplicationFiled: April 30, 2002Publication date: February 6, 2003Inventors: Guangyi Wang, Zhi Hong, Haoyun An
-
Publication number: 20030013883Abstract: The present invention is directed to a tropane analog having the structure (I) 1Type: ApplicationFiled: June 11, 2001Publication date: January 16, 2003Inventors: Gilles D. Tamagnan, Xing Fu, Ronald Martin Baldwin, Robert Innis
-
Patent number: 6506900Abstract: The invention relates to a new process for preparing a scopine ester useful as an intermediate in preparing (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4] nonane-bromide.Type: GrantFiled: August 19, 2002Date of Patent: January 14, 2003Assignee: Boehringer Ingelheim Pharma AGInventors: Rolf Banholzer, Manfred Graulich, Sven Luettke, Andreas Mathes, Helmut Meissner, Peter Specht, Wolfgang Broeder
-
Publication number: 20020198386Abstract: A lactam-aldehyde compound represented by the formula (I) shown in the specification. The lactam-aldehyde compound may be prepared by subjecting a lactone-imine compound represented by formula (III) shown in the specification to an isomerization reaction. The precursor lactone-imine compound may be prepared by rearrangement of a 3,5-dioxa-12-azawurtzitane compound.Type: ApplicationFiled: March 7, 2002Publication date: December 26, 2002Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Hiroshi Izumi, Shigeru Futamura
-
Publication number: 20020188003Abstract: Tropane derivatives having a high binding affinity and selectivity for dopamine transporters bear, on the tropane backbone either a carboxylic ester or isoxazole moiety, as well as a substituted phenyl moiety. The compounds have utility both as pharmaceutical and as imaging agents, when one or more atoms are radioactive.Type: ApplicationFiled: May 28, 2002Publication date: December 12, 2002Applicant: Research Triangle InstituteInventors: Michael J. Kuhar, Frank Ivy Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
-
Patent number: 6468998Abstract: The present invention provides a pyrrolidine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.Type: GrantFiled: May 1, 2001Date of Patent: October 22, 2002Assignee: Mitsubishi Pharma CorporationInventors: Takanobu Kuroita, Masakazu Fujio, Haruto Nakagawa
-
Patent number: 6465491Abstract: The present invention relates to certain 6-phenyl-pyridin-2-ylamine derivatives that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system disorders.Type: GrantFiled: April 4, 2001Date of Patent: October 15, 2002Assignee: Pfizer Inc.Inventors: John A. Lowe, III, Peter J. Whittle
-
Publication number: 20020128283Abstract: The invention is a process improvement for producing the carbapenem antibacterial agent (4R, 5S, 6S)-3-[[(2R, 3R)-2-[[[(S)-2-amino-3-methyl-1-oxobutyl]amino]methyl]tetrahydro-3-furanyl]thio]-6-[(R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid by hydrogenation of 4-nitrobenzyl (4R, 5S, 6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-3-{[(2R, 3R)-2-({[(2S)-3-methyl-2-({[(4-nitrobenzyl)oxy]carbonyl}amino)butanoyl]amino}methyl)-tetrahydrofuran-3-yl]thio}-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate in a biphasic solvent mixture comprising a water portion and an organic solvent portion, not containing an acid acceptor.Type: ApplicationFiled: July 9, 2001Publication date: September 12, 2002Applicant: American Home Products CorporationInventors: Tarek Mansour, Phaik-Eng Sum, Yang-I Lin, Zhong Li
-
Patent number: 6392045Abstract: The present invention discloses compounds of formula (1), any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof, wherein ---- is a single or a double bond; R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; and R1 is (a), wherein R2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, amino; aryl which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, thioalkoxy, thiocycloalkoxy, methylenedioxy, aryloxy, halogen, CF3, OCF3, CN, amino, aminoacyl, nitro, aryl and a monocyclic 5 to 6-membered heteroaryl group; a monocyclic 5 to 6-membered heteroaryl group which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, thioalkoxy, thiocycloalkoxy, methylenedioxy, aryloxy, halogen, CF3, OCF3, CN, amino, niType: GrantFiled: November 29, 1999Date of Patent: May 21, 2002Assignee: NeuroSearch A/SInventors: Dan Peters, Gunnar M. Olsen, Simon Feldbaek Nielsen, Elsebet Ostergaard Nielsen
-
Patent number: 6362195Abstract: The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula wherein R1, R2, R3 and R4 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.Type: GrantFiled: March 28, 2000Date of Patent: March 26, 2002Assignee: Pfizer Inc.Inventor: John Adams Lowe, III
-
Publication number: 20020035122Abstract: The present invention relates to novel 8-azabicyclo[3.2.1.]oct-2-ene and -octane derivatives which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of chemical substances.Type: ApplicationFiled: May 25, 2001Publication date: March 21, 2002Inventors: Dan Peters, Gunnar M. Olsen, Simon Feldbaek Nielsen, Elsebet Ostergaard Nielsen
-
Publication number: 20020032191Abstract: The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula 1Type: ApplicationFiled: March 8, 2001Publication date: March 14, 2002Inventor: John A. Lowe
-
Patent number: 6353105Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.Type: GrantFiled: May 19, 1999Date of Patent: March 5, 2002Assignees: Organix, Inc., President and Fellows of Harvard CollegeInventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Zhengming Chen
-
Publication number: 20020013337Abstract: The present invention provides compounds of the formula: 1Type: ApplicationFiled: May 25, 2001Publication date: January 31, 2002Inventors: Manoussos Perros, David Anthony Price, Blanda Luzia Christa Stammen, Anthony Wood
-
Patent number: 6329520Abstract: The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases or in determining the doses of therapeutic agents that occupy significant numbers of receptors.Type: GrantFiled: May 22, 1998Date of Patent: December 11, 2001Assignee: Research Triangle InstituteInventors: Frank I. Carroll, Michael J. Kuhar, John W. Boja, Anita H. Lewin, Philip Abraham
-
Patent number: 6323216Abstract: Novel basic derivatives of benz[e]isoindol-1-ones and pyrrolo[3,4-c]quinolin-1-ones which can be represented by the general formula (I) indicated below are described: in which X is CH or N, R is H, Cl or OR1 in which R1 is H or an alkyl group having from 1 to 3 carbon atoms, Het is the 3-endotropyl group (that is, the 8-methyl-8-azadicyclo[3.2.1]oct-3-yl group) or the 3-quinuclidyl group (that is, the 1-azadicyclo[2.2.2]oct-3-yl group); these compounds have been found to be potent and selective antagonists of the 5-HT3 serotonin-like receptor and can therefore be used, for example, as anti-emetics as well as in various pathological conditions of the central nervous system, and as antitussives.Type: GrantFiled: October 13, 1999Date of Patent: November 27, 2001Assignee: Rotta Research Laboratorium S.p.AInventors: Francesco Makovec, Andrea Cappelli, Maurizio Anzini, Salvatore Vomero, Lucio Claudio Rovati
-
Patent number: 6316624Abstract: A process for preparing a compound of formula (IV) wherein R1 is C1-4 alkyl, C1-4 haloalkyl, benzyl, C3-6 alkenyl or C3-6 alkyny, (provided that the &agr;-carbon atom of R1 is neither unsaturated nor substituted with halogen), which comprises reacting a compound of formula (III) with a source of hydroxylamine in the presence of an acid. Compounds of formula (IV) are agrochemical intermediates.Type: GrantFiled: May 30, 2000Date of Patent: November 13, 2001Assignee: Syngenta Ltd.Inventors: Martin Charles Bowden, Stephen Martin Brown
-
Patent number: 6306876Abstract: 4-[aryl(8-azabicyclo[3.2.1]octan-3yl)]aminobenzoic acid derivatives are delta-opioid receptor modulators. As delta-opioid receptor agonists, such compounds are useful as analgesics. Depending on their antagonist effect, such compounds may also be useful immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.Type: GrantFiled: December 4, 2000Date of Patent: October 23, 2001Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: John R. Carson, Robert E. Boyd, Lou Anne Neilson
-
Publication number: 20010018429Abstract: The present invention provides bicyclic metabotropic glutamate receptor ligands, as well as compositions comprising such ligands, and and methods for their use.Type: ApplicationFiled: January 25, 2001Publication date: August 30, 2001Inventors: Alan P. Kozikowski, Darryl Hugh Steensma, Werner Tueckmantel, Gian Luca Araldi
-
Publication number: 20010018444Abstract: Compounds of formula (a), (b), (c), or (d), or any mixture thereof, or a pharmaceutically-acceptable salt thereof; 1Type: ApplicationFiled: March 21, 2001Publication date: August 30, 2001Applicant: NeuroSearch A/SInventors: Jorgen Scheel-Kruger, Peter Moldt, Frank Watjen
-
Patent number: 6271381Abstract: A method for preparing a cocaine-protein conjugate easily by using a cocaine derivative having a methoxy carbonyl group and benzoyl group. This conjugate is useful for the detection of cocaine or cocaine derivatives.Type: GrantFiled: November 7, 2000Date of Patent: August 7, 2001Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Keiko Yugawa, Nobuyuki Sigetoh, Jinsei Miyazaki, Tadayasu Mitsumata
-
Patent number: 6265408Abstract: Sulphonamide compounds according to formula (I) or pharmaceutically acceptable salts thereof: wherein: Ar is naphthyl, phenyl or thienyl optionally substituted by one or more substituents selected from the group consisting of C1-6 alkyl optionally substituted by NR7R8, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkylthio, cyano, nitro, halogen, CF3, C2F5, NR7R8, CONR7R8, NR7COR8, S(O)pNR7R8, CHO, OCF3, SCF3, COR9, CH2OR9, CO2R9 or OR9 where p is 1 or 2 and R7, R8 and R9 are independently hydrogen or C1-6 alkyl. R1 and R2 are independently hydrogen or C1-6alkyl or together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring optionally substituted by Cl-6alkyl and optionally containing a further heteroatom selected from nitrogen, sulphur or oxygen, the nitrogen atom being substituted by hydrogen, C1-6 alkyl or cycloC3-7alkyl; R3 is hydrogen or C1-6 alkyl; X is oxygen, sulphur or a bond; n is 2 or 3; and m is 1 or 2; are provided.Type: GrantFiled: March 5, 1999Date of Patent: July 24, 2001Assignee: SmithKline Beecham plcInventors: Ian Thomson Forbes, Francis David King, Shirley Katherine Rahman
-
Patent number: 6262066Abstract: Novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents an optional double bond; X1 is optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X2 is —CHO, —CN, optionally substituted amino, alkyl, or aryl; or X1 is optionally substituted benzofused heterocyclyl and X2 is hydrogen; or X1 and X2 together form an optionally benzofused Spiro heterocyclyl group R1, R2, R3 and R4 are independently H and alkyl, or (R1 and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4) together can form an alkylene bridge of 1 to 3 carbon atoms; Z1 is optionally substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or —CO2(alkyl or substituted amino) or CN; Z2 is H or Z1; Z3 is H oralkyl; or Z1, Z2 and Z3, together with the carbon to which they are attached, form bicyclic saturated or unsaturated rings; pharmaceutical compositions therefore, and the use of said compounds as nociceptiType: GrantFiled: July 26, 1999Date of Patent: July 17, 2001Assignee: Schering CorporationInventors: Deen Tulshian, Ginny D. Ho, Lisa S. Silverman, Julius J. Matasi, Robbie L. McLeod, John A. Hey, Richard W. Chapman, Ana Bercovici, Francis M. Cuss
-
Patent number: 6235747Abstract: The present invention relates to certain 6-phenyl-pyridin-2-ylamine derivatives that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system disorders.Type: GrantFiled: March 13, 1997Date of Patent: May 22, 2001Assignee: Pfizer Inc.Inventors: John A. Lowe, III, Peter J. Whittle
-
Patent number: 6200991Abstract: A compound of formula (I) the process of preparing compounds of formula (I), their pharmaceutical compositions, and the method of treating diseases associated with M3 muscarinic and/or S—HT4 serotoninergic receptors.Type: GrantFiled: June 19, 2000Date of Patent: March 13, 2001Assignee: Sanofi-SynthelaboInventors: Gilles Courtemanche, GĂ©rard DeFosse, Olivier Crespin, Philippe Bovy
-
Patent number: 6177442Abstract: The invention provides a compound of formula (I): wherein A represents a bidentate group of formula —CH2—X—CH2— (wherein X is methylene, sulfur or oxygen), X′C═CY or X′WC—CYZ (wherein X′, W, Y and Z are independently hydrogen, hydroxy, acyloxy, alkoxy, alkylsilyloxy, cyano or halogen, or X′ and W or Y and Z together with the carbon to which they are attached form a carbonyl group), provided that A is not CH2—CH2; Ar is an optionally substituted phenyl or 5- or 6-membered heterocyclic ring system containing from 1 to 3 heteroatoms individually selected from nitrogen, oxygen and sulfur atoms, and at least one unsaturation (double bond) between adjacent atoms in the ring, said heterocyclic ring being optionally fused to a benzene ring; aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkanyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclylalkyl, caType: GrantFiled: July 21, 1999Date of Patent: January 23, 2001Assignee: Zeneca LimitedInventors: Christopher John Urch, Terence Lewis, Raymond Leo Sunley, Roger Salmon, Christopher Richard Ayles Godfrey, Christopher Ian Brightwell, Matthew Brian Hotson
-
Patent number: 6123917Abstract: An improved method for preparation of cocaine receptor binding ligands is provided. The method calls for the preparation of the silylaryl intermediate prepared from phenyl trimethylsilane and a anhydroecgonine methyl ester appropriately substituted. The intermediate is prepared in high purity and can be directly converted to the binding ligand by iodine substitution.Type: GrantFiled: July 31, 1995Date of Patent: September 26, 2000Assignee: Research Triangle InstituteInventor: Frank Ivy Carroll
-
Patent number: 6113877Abstract: The invention provides detectably-labeled compounds of formula (I): ##STR1## wherein A, B, C, D, E, F, R, X, Y and Z have any of the meanings given in the specification, and their pharmaceutically acceptable salts, are useful in competitive assays to assay for the presence of .sigma.2 receptors. Also disclosed are pharmaceutical compositions containing such a compound of formula (I), methods for their use and intermediates useful for preparing such compounds of formula (I).Type: GrantFiled: September 17, 1998Date of Patent: September 5, 2000Assignee: Wake Forest UniversityInventors: Robert H. Mach, Kenneth T. Wheeler, Biao Yang, Steven R. Childers
-
Patent number: 6100404Abstract: Intermediates for the preparation of compounds selected from the group consisting of a compound of the formula ##STR1## wherein R is ##STR2## n is an integer from 3 to 5, Ar is an optionally substituted heterocyclic selected from the group consisting ofType: GrantFiled: January 9, 1997Date of Patent: August 8, 2000Assignee: Hoechst Marion RousselInventors: Constantin Agouridas, Jean-Francois Chantot, Alexis Denis, Solange Gouin D'Ambrieres, Odile Le Martret
-
Patent number: 6100275Abstract: A compound having the formula, ##STR1## or any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof;whereinR is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl; andR.sup.4 isphenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF.sub.3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl;3,4-methylenedioxyphenyl;benzyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF.sub.3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl;heteroaryl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF.sub.Type: GrantFiled: May 18, 1998Date of Patent: August 8, 2000Assignee: Neurosearch A/SInventors: Peter Moldt, J.o slashed.rgen Scheel-Kruger, Gunnar M. Olsen, Elsebet .O slashed.stergaard Nielsen
-
Patent number: 6040442Abstract: The presently claimed process provides a method for preparing compounds of the formula ##STR1## phosphorous (III) compound and a diester of azodicarboxylate.Type: GrantFiled: June 1, 1995Date of Patent: March 21, 2000Assignee: Eli Lilly and CompanyInventors: Leander Merritt, John S. Ward
-
Patent number: 6030966Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.Type: GrantFiled: July 28, 1999Date of Patent: February 29, 2000Assignee: Eli Lilly and CompanyInventors: Leander Merritt, John S. Ward